Abstract
Glucagon-like peptide-1 (GLP-1) is a gut hormone that plays an important role in regulating glucose homeostasis by both its pancreatic and extrapancreatic activity. Defects of GLP-1 characterize type 2 diabetes as a primary or perhaps consequent phenomenon, resulting in inappropriately low insulin secretion after oral ingestion of nutrients. The discovery that cleavage by the ubiquitous enzyme dipeptidyl peptidase-IV (DPP-IV) is the primary route of GLP-1 metabolism formed the rationale behind the proposal to prevent degradation of endogenously released GLP-1 by DPP-IV inhibition as a novel approach to the management of type 2 diabetes. Enhanced insulin secretion as well as delayed gastric emptying, reduced glucagon secretion, and inhibited apoptosis of beta cells resulting from blockade of incretin degradation, have been proposed as the major actions of DPP-IV inhibitors as antidiabetic agents. Clinical studies to date indicate that DPP-IV inhibitors effectively ameliorate islet dysfunction and improve glucose control in patients with type 2 diabetes. They appear to have excellent therapeutic effectiveness as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. Their pharmacokinetic and pharmacodynamic profiles support once-daily dosing, with relatively few adverse effects.
Current Diabetes Reviews
Title: Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Volume: 5 Issue: 2
Author(s): Teresa Salvatore, Ornella Carbonara, Domenico Cozzolino, Roberto Torella and Ferdinando C. Sasso
Affiliation:
Abstract: Glucagon-like peptide-1 (GLP-1) is a gut hormone that plays an important role in regulating glucose homeostasis by both its pancreatic and extrapancreatic activity. Defects of GLP-1 characterize type 2 diabetes as a primary or perhaps consequent phenomenon, resulting in inappropriately low insulin secretion after oral ingestion of nutrients. The discovery that cleavage by the ubiquitous enzyme dipeptidyl peptidase-IV (DPP-IV) is the primary route of GLP-1 metabolism formed the rationale behind the proposal to prevent degradation of endogenously released GLP-1 by DPP-IV inhibition as a novel approach to the management of type 2 diabetes. Enhanced insulin secretion as well as delayed gastric emptying, reduced glucagon secretion, and inhibited apoptosis of beta cells resulting from blockade of incretin degradation, have been proposed as the major actions of DPP-IV inhibitors as antidiabetic agents. Clinical studies to date indicate that DPP-IV inhibitors effectively ameliorate islet dysfunction and improve glucose control in patients with type 2 diabetes. They appear to have excellent therapeutic effectiveness as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. Their pharmacokinetic and pharmacodynamic profiles support once-daily dosing, with relatively few adverse effects.
Export Options
About this article
Cite this article as:
Salvatore Teresa, Carbonara Ornella, Cozzolino Domenico, Torella Roberto and Sasso C. Ferdinando, Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors, Current Diabetes Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339909788166819
DOI https://dx.doi.org/10.2174/157339909788166819 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation in Parkinsons Diseases and Other Neurodegenerative Diseases: Cause and Therapeutic Implications
Current Pharmaceutical Design Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design Neuronal Semaphorins Regulate a Primary Immune Response
Current Neurovascular Research Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Physiology and Therapeutic Potential of the Thymic Peptide Thymulin
Current Pharmaceutical Design Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Effect of Halofuginone on the Pathogenesis of Autoimmune Thyroid Disease in Different Mice Models
Endocrine, Metabolic & Immune Disorders - Drug Targets CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy The Identification and Optimization of Orally Efficacious, Small Molecule VLA-4 Antagonists
Current Topics in Medicinal Chemistry IL-10 Producing Regulatory B Cells in Mice and Humans: State of the Art
Current Molecular Medicine Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Modulation of Host Cell Nucleocytoplasmic Trafficking During Picornavirus Infection
Infectious Disorders - Drug Targets Design of Protective and Therapeutic DNA Vaccines for the Treatment of Allergic Diseases
Current Drug Targets - Inflammation & Allergy Post Traumatic Lesion absence of β-Dystroglycan-Immunopositivity in Brain Vessels Coincides with the Glial Reaction and the Immunoreactivity of Vascular Laminin
Current Neurovascular Research The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials